Redenlab is contributing to a study sponsored by the Australian Department of Defence and The University of Melbourne on speech biometrics and decision making in submariners

      Redenlab are part of a successful consortium securing funding for training a new cohort of early career researchers in understanding key issues in optimal ageing (including environmental, social and economic factors that underlie health and independence in ageing).

        Redenlab Inc. are pleased to announce securing clinical trial in Cyclic Vomiting Syndrome with a Top 10 pharma company. Redenlab are providing audio capture and analytics for a Phase 1b clinical trial. Conducted in sites across the USA, the study will investigate the long-term efficacy of a treatment designed to ameliorate the impact of this rare and debilitating disease.

          Redenlab Inc. are excited to announce securing another clinical trial in Friedreich ataxia. Redenlab are providing speech analytics for a long-term open label extension clinical trial. Conducted in 8 sites across the USA over 2 years, the study will investigate the long-term efficacy of a treatment designed to ameliorate the debilitating impact of this fatal disease. For the study, Redenlab will provide advanced speech recording and analysis solutions.

            Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.

              Redenlab are proud to be supporting PTC Therapeutics, Inc. Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia.

                Learn more about the platforms and applications that Redenlab use for software development, documentation, and quality management that is in-line with standards such as FDA 21 CFR Part 22.

                  Redenlab has entered into a 5 year collaboration with investigators from North and South America, Australia and Europe to investigate the underlying neural mechanisms of Friedreich ataxia. The study is supported by the Friedreich's Ataxia Research Alliance (FARA) and pharmaceutical industry partners.